EA201490800A1 - Способ ингибирования деубиквитинирующей активности - Google Patents

Способ ингибирования деубиквитинирующей активности

Info

Publication number
EA201490800A1
EA201490800A1 EA201490800A EA201490800A EA201490800A1 EA 201490800 A1 EA201490800 A1 EA 201490800A1 EA 201490800 A EA201490800 A EA 201490800A EA 201490800 A EA201490800 A EA 201490800A EA 201490800 A1 EA201490800 A1 EA 201490800A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activity
deubuctivating
inhibiting
compound
dub
Prior art date
Application number
EA201490800A
Other languages
English (en)
Other versions
EA026409B1 (ru
Inventor
Стиг Линдер
Рольф Ларссон
Original Assignee
Виволюкс Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виволюкс Аб filed Critical Виволюкс Аб
Publication of EA201490800A1 publication Critical patent/EA201490800A1/ru
Publication of EA026409B1 publication Critical patent/EA026409B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединение общей структуры (I) способно аннулировать деубиквитинирующую (DUB) активность 19S RP DUB. Соединение можно применять для лечения рака, в частности рака, невосприимчивого к лечению современной химиотерапией. Также раскрыты соответствующие способы лечения и фармацевтическая композиция, содержащая данное соединение.
EA201490800A 2011-10-19 2012-10-15 Соединение, ингибирующее деубиквитинирующую активность, и использование его в композиции и в способе лечения рака EA026409B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1200303 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (2)

Publication Number Publication Date
EA201490800A1 true EA201490800A1 (ru) 2014-09-30
EA026409B1 EA026409B1 (ru) 2017-04-28

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490800A EA026409B1 (ru) 2011-10-19 2012-10-15 Соединение, ингибирующее деубиквитинирующую активность, и использование его в композиции и в способе лечения рака

Country Status (22)

Country Link
US (1) US9221761B2 (ru)
EP (1) EP2780326B1 (ru)
JP (1) JP6165748B2 (ru)
KR (1) KR102022575B1 (ru)
CN (1) CN104271557B (ru)
AU (1) AU2012326682B2 (ru)
BR (1) BR112014009365B1 (ru)
CA (1) CA2852518C (ru)
CL (1) CL2014000998A1 (ru)
DK (1) DK2780326T3 (ru)
EA (1) EA026409B1 (ru)
ES (1) ES2713484T3 (ru)
HK (1) HK1203194A1 (ru)
HU (1) HUE041816T2 (ru)
IL (1) IL232118A (ru)
MX (1) MX345467B (ru)
MY (1) MY169330A (ru)
PL (1) PL2780326T3 (ru)
PT (1) PT2780326T (ru)
SG (1) SG11201401608PA (ru)
WO (1) WO2013058691A1 (ru)
ZA (1) ZA201403302B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271557B (zh) * 2011-10-19 2017-12-05 威沃路克斯股份公司 去泛素化活性的抑制方法
AU2013370417A1 (en) 2012-12-28 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
BR112017020900B1 (pt) * 2015-03-30 2023-02-23 Mission Therapeutics Limited Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
KR102636859B1 (ko) * 2017-01-30 2024-02-14 업 테라퓨틱스 인코포레이티드 암, 당뇨병 및 신경 장애의 치료를 위한 신규한 스피로 및 사이클릭 비스-벤질리딘 프로테아좀 억제제
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779230C (en) * 1999-12-03 2006-05-25 Emory University Curcumin analogues for treating cancer
CA2478522A1 (en) * 2002-03-08 2003-09-18 Emory University Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
US20070010488A1 (en) * 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
ATE411300T1 (de) * 2005-08-05 2008-10-15 Hybrigenics Sa Neue cysteine protease hemmers und ihre therapeutische anwendungen
US7582655B2 (en) * 2005-11-22 2009-09-01 University Of Saskatchewan Antineoplastic compounds
WO2011005790A1 (en) * 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers
CN104271557B (zh) * 2011-10-19 2017-12-05 威沃路克斯股份公司 去泛素化活性的抑制方法

Also Published As

Publication number Publication date
HK1203194A1 (en) 2015-10-23
US20140228354A1 (en) 2014-08-14
EP2780326B1 (en) 2018-12-26
PL2780326T3 (pl) 2019-06-28
EA026409B1 (ru) 2017-04-28
CN104271557A (zh) 2015-01-07
KR20140078742A (ko) 2014-06-25
NZ624019A (en) 2016-07-29
IL232118A (en) 2016-06-30
EP2780326A1 (en) 2014-09-24
KR102022575B1 (ko) 2019-09-18
SG11201401608PA (en) 2014-07-30
CA2852518C (en) 2019-09-24
PT2780326T (pt) 2019-03-04
EP2780326A4 (en) 2015-04-22
JP2014530852A (ja) 2014-11-20
CL2014000998A1 (es) 2014-10-10
IL232118A0 (en) 2014-05-28
ZA201403302B (en) 2015-05-27
MX345467B (es) 2017-02-01
ES2713484T3 (es) 2019-05-22
US9221761B2 (en) 2015-12-29
BR112014009365A2 (pt) 2017-04-18
HUE041816T2 (hu) 2019-05-28
WO2013058691A1 (en) 2013-04-25
AU2012326682B2 (en) 2016-02-18
BR112014009365B1 (pt) 2021-08-03
DK2780326T3 (en) 2019-03-04
AU2012326682A1 (en) 2014-05-01
MY169330A (en) 2019-03-21
JP6165748B2 (ja) 2017-07-19
CN104271557B (zh) 2017-12-05
MX2014004646A (es) 2014-08-01
CA2852518A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
EA201490800A1 (ru) Способ ингибирования деубиквитинирующей активности
ZA201700572B (en) Therapeutically active compounds and their methods of use
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
UA122324C2 (uk) Терапевтично активні сполуки і способи їх застосування
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
TW201611843A (en) Methods of treatment with arginine deiminase
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201590987A1 (ru) Соединения и способы их применения
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
PH12014501639A1 (en) Pharmaceutical compositions and methods
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2013012785A (es) Tratamiento del mieloma multiple.
MX360774B (es) Antagonistas de progesterona.
WO2013112699A3 (en) Proteasome activity enhancing compounds
PH12015501088A1 (en) Dimeric compounds
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
NZ628433A (en) Chitosan-derived compositions
EA201491500A1 (ru) Способы лечения фиброза

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM